Conclusions drawn from the study and clinical implications
The specific and significant COVID-19 risk of ADE should have been and
should be clearly and emphatically disclosed to research subjects
currently in vaccine trials, as well as those being recruited for the
trials and future patients after vaccine approval, in order to meet the
medical ethics standard of patient comprehension.